Advertisement

FDG-PET Imaging of Doxorubicin-Induced Cardiotoxicity: a New Window on an Old Problem

  • Matteo BaucknehtEmail author
  • Vanessa Cossu
  • Alberto Miceli
  • Maria Isabella Donegani
  • Selene Capitanio
  • Silvia Morbelli
  • Cecilia Marini
  • Gianmario Sambuceti
Cardiac Nuclear Imaging (A Cuocolo and M Petretta, Section Editors)
  • 26 Downloads
Part of the following topical collections:
  1. Topical Collection on Cardiac Nuclear Imaging

Abstract

Purpose of Review

The present review focus on the published literature about the use of 18F-fluorodeoxyglucose (FDG) PET/CT imaging in the early recognition of anthracyclines-related cardiotoxicity.

Recent Findings

The application of PET/CT may represent an early predictor of subsequent cardiotoxicity in cancer patients treated with doxorubicin (DXR). However, the application of PET/CT may also extend beyond mere cardiotoxicity identification and monitoring to provide mechanistic delineation of the cardiotoxic pathophysiology. Indeed, this tool further enriched the current knowledge on energy metabolism impairment in the DXR-induced cardiotoxic cascade.

Summary

The capability of FDG to selectively track the early endoplasmic reticulum pentose phosphate pathway (PPP) response to oxidative stress rather than the later occurring contractile dysfunction might imply the abrupt occurrence of metabolic abnormality during the course of chemotherapy, possibly identifying the ongoing myocardial damage in time to change the chemotherapy scheme or to initiate targeted cardioprotective treatments. Future prospective studies encompassing a specific dietary or pharmacologic preparation before FDG injection, as already performed in infectious and inflammatory heart diseases, are needed to move the obtained preclinical findings supporting the role of FDG imaging in DXR cardiotoxicity from bench to bedside.

Keywords

Cardiotoxicity Fluorodeoxyglucose Positron emission tomography Doxorubicin Oxidative stress 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Ellison LF. Progress in net cancer survival in Canada over 20 years. Health Rep. 2018;29:10–8.PubMedGoogle Scholar
  2. 2.
    Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics. CA Cancer J Clin. 2016;66:271–89.  https://doi.org/10.3322/caac.21349. CrossRefPubMedGoogle Scholar
  3. 3.
    Maejima Y, Adachi S, Ito H, Hirao K, Isobe M. Induction of premature senescence in cardiomyocytes by doxorubicin as a novel mechanism of myocardial damage. Aging Cell. 2008;7:125–36.CrossRefGoogle Scholar
  4. 4.
    • Mercurio V, Pirozzi F, Lazzarini E, Marone G, Rizzo P, Agnetti G, et al. Models of heart failure based on the cardiotoxicity of anticancer drugs. J Card Fail. 2016;22:449–58.  https://doi.org/10.1016/j.cardfail.2016.04.008. Interesting review of the proposed models of heart failure based on the cardiotoxicity of antineoplastic drugs, including the heart failure resulting from the combination of oxidative stress, mitochondrial dysfunction, and activation of the DNA damage response, which is typically caused by anthracyclines.CrossRefPubMedGoogle Scholar
  5. 5.
    Dickey JS, Rao VA. Current and proposed biomarkers of anthracycline cardiotoxicity in cancer: emerging opportunities in oxidative damage and autophagy. Curr Mol Med. 2012;12:763–71.CrossRefGoogle Scholar
  6. 6.
    Marshall RC, Tillisch JH, Phelps ME, Huang SC, Carson R, Henze E, et al. Identification and differentiation of resting myocardial ischemia and infarction in man with positron computed tomography, 18F-labeled fluorodeoxyglucose and N-13 ammonia. Circulation. 1983;67:766–78.  https://doi.org/10.1161/01.cir.67.4.766.CrossRefPubMedGoogle Scholar
  7. 7.
    Inglese E, Leva L, Matheoud R, Sacchetti G, Secco C, Gandolfo P, et al. Spatial and temporal heterogeneity of regional myocardial uptake in patients without heart disease under fasting conditions on repeated whole-body 18F-FDG PET/CT. J Nucl Med. 2007;48:1662–9.  https://doi.org/10.2967/jnumed.107.041574.CrossRefPubMedGoogle Scholar
  8. 8.
    Borde C, Kand P, Basu S. Enhanced myocardial fluorodeoxyglucose uptake following Adriamycin-based therapy: evidence of early chemotherapeutic cardiotoxicity? World J Radiol. 2012;4:220–3.  https://doi.org/10.4329/wjr.v4.i5.220.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    •• Bauckneht M, Ferrarazzo G, Fiz F, Morbelli S, Sarocchi M, Pastorino F, et al. Doxorubicin effect on myocardial metabolism as a prerequisite for subsequent development of cardiac toxicity: a translational 18F-FDG PET/CT observation. J Nucl Med. 2017;58:1638–45.  https://doi.org/10.2967/jnumed.117.191122. The first clinical observation of the correlation between myocardial FDG uptake and cardiotoxicity in a group of HL patients successfully treated with DXR.CrossRefPubMedGoogle Scholar
  10. 10.
    Sarocchi M, Bauckneht M, Arboscello E, Capitanio S, Marini C, Morbelli S, et al. An increase in myocardial 18-fluorodeoxyglucose uptake is associated with left ventricular ejection fraction decline in Hodgkin lymphoma patients treated with anthracycline. J Transl Med. 2018;16:295.  https://doi.org/10.1186/s12967-018-1670-9.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    •• Kim J, Cho SG, Kang SR, Yoo SW, Kwon SY, Min JJ, et al. Association between FDG uptake in the right ventricular myocardium and cancer therapy-induced cardiotoxicity. J Nucl Cardiol. 2019.  https://doi.org/10.1007/s12350-019-01617-y. The correlation between myocardial FDG uptake and the subsequent development of cardiotoxicity in a group of breast cancer patients treated with anthracyclines or trastuzumab, further suggesting that oncologic FDG PET/CT scans can provide information regarding cancer therapy-induced cardiotoxicity as well as tumor response.
  12. 12.
    Keramida K, Farmakis D, Bingcang J, Sulemane S, Sutherland S, Bingcang RA, et al. Longitudinal changes of right ventricular deformation mechanics during trastuzumab therapy in breast cancer patients. Eur J Heart Fail. 2019;21:529–35.  https://doi.org/10.1002/ejhf.1385.CrossRefPubMedGoogle Scholar
  13. 13.
    Hrelia S, Fiorentini D, Maraldi T, Angeloni C, Bordoni A, Biagi PL, et al. Doxorubicin induces early lipid peroxidation associated with changes in glucose transport in cultured cardiomyocytes. Biochim Biophys Acta. 2002;1567:150–6.  https://doi.org/10.1016/s0005-2736(02)00612-0. CrossRefPubMedGoogle Scholar
  14. 14.
    Carvalho RA, Sousa RP, Cadete VJ, Lopaschuk GD, Palmeira CM, Bjork JA, et al. Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy. Toxicology. 2010;270:92–8.  https://doi.org/10.1016/j.tox.2010.01.019.CrossRefPubMedGoogle Scholar
  15. 15.
    Tokarska-Schlattner M, Zaugg M, da Silva R, Lucchinetti E, Schaub MC, Wallimann T, et al. Acute toxicity of doxorubicin on isolated perfused heart: response of kinases regulating energy supply. Am J Physiol Heart Circ Physiol. 2005;289:H37–47.  https://doi.org/10.1152/ajpheart.01057.2004.CrossRefPubMedGoogle Scholar
  16. 16.
    •• Bauckneht M, Pastorino F, Castellani P, Cossu V, Orengo AM, Piccioli P, et al. Increased myocardial 18F-FDG uptake as a marker of doxorubicin-induced oxidative stress. J Nucl Cardiol. 2019.  https://doi.org/10.1007/s12350-019-01618-x The preclinical data supporting the pathophysiological interpretation of the increased myocardial FDG uptake following DXR exposure.
  17. 17.
    Clarke JL, Mason PJ. Murine hexose-6-phosphate dehydrogenase: a bifunctional enzyme with broad substrate specificity and 6-phosphogluconolactonase activity. Arch Biochem Biophys. 2003;415:229–34.  https://doi.org/10.1016/s0003-9861(03)00229-7.CrossRefPubMedGoogle Scholar
  18. 18.
    Cossu V, Marini C, Piccioli P, Rocchi A, Bruno S, Orengo AM, et al. Obligatory role of endoplasmic reticulum in brain FDG uptake. Eur J Nucl Med Mol Imaging. 2019;46:1184–96.  https://doi.org/10.1007/s00259-018-4254-2.CrossRefPubMedGoogle Scholar
  19. 19.
    Buschiazzo A, Cossu V, Bauckneht M, Orengo A, Piccioli P, Emionite L, et al. Effect of starvation on brain glucose metabolism and 18F-2-fluoro-2-deoxyglucose uptake: an experimental in-vivo and ex-vivo study. EJNMMI Res. 2018;8:44.  https://doi.org/10.1186/s13550-018-0398-0.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Marini C, Ravera S, Buschiazzo A, Bianchi G, Orengo AM, Bruno S, et al. Discovery of a novel glucose metabolism in cancer: the role of endoplasmic reticulum beyond glycolysis and pentose phosphate shunt. Sci Rep. 2016;6:25092.  https://doi.org/10.1038/srep25092.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Marini C, Bianchi G, Buschiazzo A, Ravera S, Martella R, Bottoni G, et al. Divergent targets of glycolysis and oxidative phosphorylation result in additive effects of metformin and starvation in colon and breast cancer. Sci Rep. 2016;6:19569.  https://doi.org/10.1038/srep19569.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Scussolini M, Bauckneht M, Cossu V, Bruno S, Orengo AM, Piccioli P, et al. G6Pase location in the endoplasmic reticulum: implications on compartmental analysis of FDG uptake in cancer cells. Sci Rep. 2019;9:2794.  https://doi.org/10.1038/s41598-019-38973-1.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    •• Tsachaki M, Mladenovic N, Štambergová H, Birk J, Odermatt A. Hexose-6-phosphate dehydrogenase controls cancer cell proliferation and migration through pleiotropic effects on the unfolded-protein response, calcium homeostasis, and redox balance. FASEB J. 2018;32:2690–705.  https://doi.org/10.1096/fj.201700870RR This study shows the mechanism through which H6PD exerts its effects by H6PD silencing in cancer cells. Knockdown of H6PD resulted in an increase in ER lumen oxidation, and an increase in sarco/endoplasmic reticulum Ca2+-ATPase-2 pump expression and decrease in inositol trisphosphate receptor-III, which led to augmented levels of calcium in the ER, suggesting the strict connection between H6PD enzymatic activity, reticular antioxidant response and calcium homeostasis.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Salvemini F, Franze A, Iervolino A, Filosa S, Salzano S, Ursini MV. Enhanced glutathione levels and oxidoresistance mediated by increased glucose-6-phosphate dehydrogenase expression. J Biol Chem. 1999;274:2750–7.  https://doi.org/10.1074/jbc.274.5.2750.CrossRefPubMedGoogle Scholar
  25. 25.
    Filosa S, Fico A, Paglialunga F, Balestrieri M, Crooke A, Verde P, et al. Failure to increase glucose consumption through the pentose-phosphate pathway results in the death of glucose-6-phosphate dehydrogenase gene-deleted mouse embryonic stem cells subjected to oxidative stress. Biochem J. 2003;370:935–43.  https://doi.org/10.1042/BJ20021614.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Fico A, Paglialunga F, Cigliano L, Abrescia P, Verde P, Martini G, et al. Glucose-6-phosphate dehydrogenase plays a crucial role in protection from redox-stress-induced apoptosis. Cell Death Differ. 2004;11:823–31.  https://doi.org/10.1038/sj.cdd.4401420.CrossRefPubMedGoogle Scholar
  27. 27.
    Rogoff D, Black K, McMillan DR, White PC. Contribution of hexose-6-phosphate dehydrogenase to NADPH content and redox environment in the endoplasmic reticulum. Redox Rep. 2010;15:64–70.  https://doi.org/10.1179/174329210X12650506623249.CrossRefPubMedGoogle Scholar
  28. 28.
    Paik JY, Jung KH, Lee JH, Park JW, Lee KH. Reactive oxygen species-driven HIF1α triggers accelerated glycolysis in endothelial cells exposed to low oxygen tension. Nucl Med Biol. 2017;45:8–14.  https://doi.org/10.1016/j.nucmedbio.2016.10.006.CrossRefPubMedGoogle Scholar
  29. 29.
    Yan R, Song J, Wu Z, Guo M, Liu J, Li J, et al. Detection of myocardial metabolic abnormalities by 18F-FDG PET/CT and corresponding pathological changes in beagles with local heart irradiation. Korean J Radiol. 2015;16:919–28.  https://doi.org/10.3348/kjr.2015.16.4.919. CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Evans JD, Gomez DR, Chang JY, Gladish GW, Erasmus JJ, Rebueno N, et al. Cardiac 18F-fluorodeoxyglucose uptake on positron emission tomography after thoracic stereotactic body radiation therapy. Radiother Oncol. 2013;109:82–8.  https://doi.org/10.1016/j.radonc.2013.07.021.CrossRefPubMedGoogle Scholar
  31. 31.
    Liu FF, Stone JR, Schuldt AJ, Okoshi K, Okoshi MP, Nakayama M, et al. Heterozygous knockout of neuregulin-1 gene in mice exacerbates doxorubicin-induced heart failure. Am J Physiol Heart Circ Physiol. 2005;289:H660–6.  https://doi.org/10.1152/ajpheart.00268.2005.CrossRefPubMedGoogle Scholar
  32. 32.
    Bulten BF, Sollini M, Boni R, Massri K, de Geus-Oei LF, van Laarhoven HWM, et al. Cardiac molecular pathways influenced by doxorubicin treatment in mice. Sci Rep. 2019;9:2514.  https://doi.org/10.1038/s41598-019-38986-w.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Seino H, Ono S, Miura H, Morohashi S, Wu Y, Tsushima F, et al. Hypoxia is important in F-18 FDG accumulation in thecoma-fibroma tumors on F-18 FDG PET/CT scans. Mol Med Rep. 2016;13:3821–7.  https://doi.org/10.3892/mmr.2016.5016.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Todorova VK, Beggs ML, Delongchamp RR, Dhakal I, Makhoul I, Wei JY, et al. Transcriptome profiling of peripheral blood cells identifies potential biomarkers for doxorubicin cardiotoxicity in a rat model. PLoS One. 2012;7:e48398.  https://doi.org/10.1371/journal.pone.0048398.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Manabe O, Yoshinaga K, Ohira H, Masuda A, Sato T, Tsujino I, et al. The effects of 18-h fasting with low-carbohydrate diet preparation on suppressed physiological myocardial 18F fluorodeoxyglucose (FDG) uptake and possible minimal effects of unfractionated heparin use in patients with suspected cardiac involvement sarcoidosis. J Nucl Cardiol. 2016;23:244–52.  https://doi.org/10.1007/s12350-015-0226-0.CrossRefGoogle Scholar
  36. 36.
    Chen W, Sajadi MM, Dilsizian V. Merits of FDG PET/CT and functional molecular imaging over anatomic imaging with echocardiography and CT angiography for the diagnosis of cardiac device infections. JACC Cardiovasc Imaging. 2018;11:1679–91.  https://doi.org/10.1016/j.jcmg.2018.08.026.CrossRefPubMedGoogle Scholar
  37. 37.
    Genovesi D, Bauckneht M, Altini C, Popescu CE, Ferro P, Monaco L, et al. The role of positron emission tomography in the assessment of cardiac sarcoidosis. Br J Radiol. 2019;92:20190247.  https://doi.org/10.1259/bjr.20190247.CrossRefPubMedGoogle Scholar
  38. 38.
    Bauckneht M, Morbelli S, Fiz F, Ferrarazzo G, Piva R, Nieri A, Sarocchi M, Spallarossa P, Canepari M, Arboscello E, Bellodi A, Massaia M, Gallamini A, Bruzzi P, Marini C, Sambuceti G A score-based approach to 18F-FDG PET images as a tool to describe metabolic predictors of myocardial doxorubicin susceptibility. Diagnostics (Basel) 2017;7. Doi:  https://doi.org/10.3390/diagnostics7040057.CrossRefGoogle Scholar
  39. 39.
    Keyes JW. SUV: standard uptake or silly useless value? J Nucl Med. 1995;36:1836–9.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Nuclear Medicine UnitIRCCS Ospedale Policlinico San MartinoGenoaItaly
  2. 2.Department of Health Sciences (DISSAL)University of GenovaGenoaItaly
  3. 3.CNR Institute of Molecular Bioimaging and PhysiologyMilanItaly

Personalised recommendations